Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- Profit Warnings & Insulin PricingEpisode 104 — 07 September 2026HCA's profit warning signals access erosion, subcutaneous Leqembi challenges cost-effectiveness, FTC insulin settlement reshapes PBMs, and ICER expands early-phase advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- Market Access Headlines: HCA, Leqembi, Insulin, ICEREpisode 103 — 06 September 2026This week: HCA's profit warning signals US access erosion, subcutaneous Leqembi approval shifts Alzheimer's HEOR, FTC insulin settlement reshapes competition, and ICER expands early-phase scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- Elections, AI, and Value PricingEpisode 102 — 04 September 2026Examining how US election outcomes may reshape drug pricing, AI's growing role in HTA evidence, oncology value-based pricing hurdles, and the evolving patient-centricity in HTA.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTA in Fragile SettingsEpisode 101 — 03 September 2026Examining HTA methodologies in humanitarian crises, incorporating social determinants, blockchain for RWE security, and post-Brexit access challenges in Northern Ireland.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
- Patient Advocacy & HTA EvolutionEpisode 100 — 02 September 2026Examining the evolving role of patient advocacy in evidence generation, ESG integration into pricing, value demonstration challenges for first-in-class drugs, and HTA development in low-resource settings.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- HCA Warning, Leqembi SubQ, FTC InsulinEpisode 99 — 01 September 2026Examining HCA's profit warning, subcutaneous Leqembi's HEOR challenges, FTC insulin settlement implications, and ICER's scientific advice expansion.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- Leqembi SubQ, HCA Access, FTC Insulin, ICER AdviceEpisode 98 — 31 August 2026Examining subcutaneous Leqembi’s access potential, HCA’s uninsured care surge, CVS insulin settlement dynamics, and ICER’s early-phase evidence shift.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTA Method Shifts & RWE ExpansionEpisode 97 — 30 August 2026Examining evolving HTA methodologies across Asia-Pacific, RWE integration hurdles in Latin America, gene therapy HEOR strategies in Asia, and digital therapeutics' real-world utility.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast12 min
- Accelerated Approvals & Value ModelsEpisode 96 — 29 August 2026Examining FDA's real-world evidence guidance for accelerated approvals, CMS's Medicare Advantage Star Rating updates, NICE's threshold consultation for specialized tech, and EMA's adaptive licensing initiative for rare diseases.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- HCA Warning & Leqembi ApprovalEpisode 95 — 28 August 2026HCA's profit warning signals US healthcare access stress; subQ Leqembi approval raises HEOR questions; FTC settlement reshapes insulin pricing dynamics; ICER expands scientific advice for novel therapies.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.